The Association Between Location of BRCA Mutation and Efficacy of PARP Inhibitor as a Frontline Maintenance Therapy in Advanced Epithelial Ovarian Cancer.

• Tác giả: Hyeong In Ha, Eun Taeg Kim, Ji Hyun Kim, Sang Wun Kim, Se Ik Kim, Sunghoon Kim, Young Tae Kim, Dong-Eun Lee, Jung-Yun Lee, Yong Jae Lee, Myong Cheol Lim, Eun-Ji Nam, Sang-Yoon Park
• Ngôn ngữ: eng
• Thông tin xuất bản: Switzerland : Cancers , 2025
• Bộ sưu tập: NCBI
• ID: 704417

Tóm tắt

BACKGROUND: The location of BRCA mutations within functional domains may affect sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapy. This study aimed to evaluate the progression-free survival (PFS) benefit from the PARP inhibitor in relation to the location of mutations in MATERIALS AND METHODS: Patients with advanced stage III-IV epithelial ovarian cancer who had deleterious RESULTS: Of the 380 patients, 242 (63.7%) harbored CONCLUSIONS: Frontline PARP inhibitor maintenance therapy demonstrated a significant PFS benefit in patients with